Posters

      Plasma Protein Biomarker Identification for Monitoring Molecular Changes in Smokers, Former Smokers, and E-Vapor Product Users Compared with Never Smokers

      Nury, C.; Eb-Levadoux, Y.; Kolli, A.; Poussin, C.; Curran, T. M.; Baglia, L. A.; Berg, R. A.; Felber Medlin , L.; Ansari, S.; Kishazi, E.; Martin, F.; Titz, B.; Picavet, P.; Ivanov, N. V.; Spinelli, S. L.; Hoeng, J.; Peitsch, M. C.

      Conference date
      Oct 19, 2020
      Conference name
      Human Proteome Organization World Congress (HUPO Connect 2020)
      Link to more information
      Link to more information
      Topic
      Summary

      No abstract available.

      Related Publications

      Lipidomics in Multi-Omics Studies

      Pre-clinical Toxicology Systems Toxicology

      Toxicological evaluation of the Tobacco Heating System 2.2, a candidate modified risk tobacco product in a OECD inhalation study complemented with systems toxicology

      Pre-clinical Toxicology Systems Toxicology

      Toxicological evaluation of the Tobacco Heating System 2.2, a candidate Modified Risk Tobacco Product in a 90-Day OECD inhalation study complemented with systems toxicology

      Pre-clinical Toxicology Systems Toxicology

      Impact of cigarette smoke and Modified Risk Tobacco Products (MRTPs) on DNA methylation

      Pre-clinical Toxicology Systems Toxicology

      Effects Of Cigarette Smoke On The High Fat Diet-Induced ApoE-/- Mouse Model Of Diabetic Atherosclerosis

      Pre-clinical Toxicology Systems Toxicology

      Chronological Changes in BEAS-2B Cells Chronically Exposed to Cigarette Smoke Total Particulate Matter

      Pre-clinical Toxicology Systems Toxicology

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts to develop and assess products that have the potential to reduce individual risk and population harm associated with tobacco use. This site is for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not for advertising or marketing. It is not intended for use by consumers.

      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. Our RRPs are smoke-free products that produce an aerosol that contains far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.